Literature DB >> 6393868

Prospective randomized double-blind comparison of nephrotoxicity and auditory toxicity of tobramycin and netilmicin.

J M Gatell, J G SanMiguel, V Araujo, L Zamora, J Maña, M Ferrer, M Bonet, M Bohe, M T Jimenez de Anta.   

Abstract

Netilmicin or tobramycin was administered to 197 patients in a prospective randomized double-blind trial. Of these patients, 140 recipients of nine or more doses of netilmicin or tobramycin could be evaluated for nephrotoxicity. Fifty-five patients were able to cooperate in the administration of serial audiograms. Nephrotoxicity of similar severity developed in 7 of 73 (9.6%) recipients of tobramycin and in 7 of 67 (10.4%) recipients of netilmicin (P greater than 0.05). Mild or slight auditory toxicity developed in 5 of 28 (17.8%) recipients of tobramycin and in 2 of 27 (7.4%) recipients of netilmicin (P greater than 0.05).

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6393868      PMCID： PMC180010          DOI： 10.1128/AAC.26.5.766

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  34 in total

1.  Tobramycin nephrotoxicity. A prospective clinical study.

Authors:  A Coca; J Blade; A Martinez; F Segura; E Soriano; M Ribas-Mundo
Journal:  Postgrad Med J       Date:  1979-11       Impact factor: 2.401

2.  Prospective comparative study of efficacy and toxicity of netilmicin and amikacin.

Authors:  B V Bock; P H Edelstein; R D Meyer
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity.

Authors:  M Barza; M W Lauermann; F P Tally; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  Comparative nephrotoxicities of gentamicin, netilmicin and tobramycin in the rat.

Authors:  L Soberon; R L Bowman; E Pastoriza-Munoz; G J Kaloyanides
Journal:  J Pharmacol Exp Ther       Date:  1979-09       Impact factor: 4.030

5.  Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer.

Authors:  L J Love; S C Schimpff; D M Hahn; V M Young; H C Standiford; J F Bender; C L Fortner; P H Wiernik
Journal:  Am J Med       Date:  1979-04       Impact factor: 4.965

6.  Comparative nephrotoxicities of high-dose netilmicin and tobramycin in rats.

Authors:  R A Parker; D N Gilbert; D C Houghton; G A Porter; W M Bennett
Journal:  Antimicrob Agents Chemother       Date:  1980-08       Impact factor: 5.191

7.  Multicenter comparative evaluation of netilmicin and gentamicin in adult patients. Efficacy and safety.

Authors:  R L Herting; R R Lorber; M Miller; M R Danzig
Journal:  Arzneimittelforschung       Date:  1981

8.  Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

Authors:  C R Smith; J J Lipsky; O L Laskin; D B Hellmann; E D Mellits; J Longstreth; P S Lietman
Journal:  N Engl J Med       Date:  1980-05-15       Impact factor: 91.245

9.  Netilmicin treatment of complicated urinary tract infection in patients with renal function impairment.

Authors:  N Frimodt-Möller; S Maigaard; P O Madsen
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides.

Authors:  J J Schentag; F M Gengo; M E Plaut; D Danner; A Mangione; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1979-10       Impact factor: 5.191
View more
  5 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

2.  Urinary alanine-aminopeptidase (AAP) excretion in patients with urinary tract infection treated with ceftazidime (CAZ) or cefotaxime (CTX) plus tobramycin (TOB).

Authors:  A Wiecek; F Kokot; W Grzeszczak
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

3.  Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.

Authors:  S S Pedersen; T Jensen; D Osterhammel; P Osterhammel
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

4.  Univariate and multivariate analyses of risk factors predisposing to auditory toxicity in patients receiving aminoglycosides.

Authors:  J M Gatell; F Ferran; V Araujo; M Bonet; E Soriano; J Traserra; J G SanMiguel
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

Review 5.  Experimental, clinical and preventive aspects of ototoxicity.

Authors:  A A Chiodo; P W Alberti
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.